Summit Therapeutics plc Exercise Of Restricted Stock Units
December 24 2019 - 1:00AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Exercise of Restricted Stock Units
Oxford, UK, and Cambridge, MA, US, 24 December 2019 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by
Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted
stock units ('RSUs') that entitled the holder to subscribe for an
ordinary share of one penny nominal value at a subscription price of one
penny per ordinary share.
The RSUs were granted under the Company's 2017 Remuneration Policy and
were eligible for exercise for a limited time after completion of a
vesting period of one year. Details of the exercise of the RSUs, all of
which took place on 23 December 2019, and which have been duly notified
to the Company, are summarised below.
% of Issued
RSU's Shareholding Share
Director Position Exercised (ordinary shares) Capital
------------- -------------- ------------- ------------------ ------------
Leopoldo Non-Executive
Zambeletti Director 17,073 33,052 0.02%
------------- -------------- ------------- ------------------ ------------
Application has been made to the London Stock Exchange for the admission
of 17,073 ordinary shares to trading on AIM and it is expected that
admission will become effective and that dealings will commence at 8.00
a.m. on or around 31 December 2019.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit
Richard Pye (UK office) Tel: +44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
Notification of Transactions pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the persons discharging managerial responsibilities/person
closely associated
--------------------------------------------------------------------------------------
a) Name (i) Leopoldo Zambeletti
------------------------ ------------------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status (i) Non-Executive Director
------------------------ ------------------------------------------------------------
b) Initial notification / Initial notification
Amendment
------------------------ ------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Summit Therapeutics plc
------------------------ ------------------------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
------------------------ ------------------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
------------------------ ------------------------------------------------------------
b) Nature of the Exercise of restricted stock units (RSUs) to subscribe
transactions for ordinary shares of one penny nominal value
------------------------ ------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------ ----------------------------- -------------------------
(i) 1p (exercise price) (i) 17,073
------------------------ ----------------------------- -------------------------
d) Aggregated information
- Aggregated volume 17,073 ordinary shares
- Price 1 penny (exercise price)
------------------------ ------------------------------------------------------------
e) Date of the transactions 23 December 2019
------------------------ ------------------------------------------------------------
f) Place of the Outside a trading venue
transactions
------------------------ ------------------------------------------------------------
-END-
(END) Dow Jones Newswires
December 24, 2019 02:00 ET (07:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More Summit Therapeutics Plc News Articles